Basit öğe kaydını göster

dc.contributor.authorOzdogu, Hakan
dc.contributor.authorRubio, Marie Therese
dc.contributor.authorD'Aveni-Piney, Maud
dc.contributor.authorLabopin, Myriam
dc.contributor.authorHamladji, Rose-Marie
dc.contributor.authorSanz, Miguel A.
dc.contributor.authorBlaise, Didier
dc.contributor.authorDaguindeau, Etienne
dc.contributor.authorRichard, Carlos
dc.contributor.authorSantarone, Stella
dc.contributor.authorIrrera, Giuseppe
dc.contributor.authorYakoub-Agha, Ibrahim
dc.contributor.authorYeshurun, Moshe
dc.contributor.authorDiez-Martin, Jose L.
dc.contributor.authorMohty, Mohamad
dc.contributor.authorSavani, Bipin N.
dc.contributor.authorNagler, Arnon
dc.date.accessioned2019-06-14T07:14:49Z
dc.date.available2019-06-14T07:14:49Z
dc.date.issued2017
dc.identifier.issn1756-8722
dc.identifier.urihttps://jhoonline.biomedcentral.com/track/pdf/10.1186/s13045-016-0389-4
dc.identifier.urihttp://hdl.handle.net/11727/3538
dc.description.abstractBackground: The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored. Methods: We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate. Results: Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (GVHD) (31 vs. 52%, p = 0.0002) and of its extensive form (8 vs. 26%, p < 0.0001) but similar relapse incidence (22 vs. 27%, p = 0.23) leading to improved GVHD and relapse-free survival (GRFS) (60 vs. 40%, p = 0.0001). In multivariate analyses, the addition of ATG was independently associated with lower chronic GVHD (HR = 0.46, p = 0.0001), improved leukemia-free survival (HR = 0.67, p = 0.027), overall survival (HR = 0.65, p = 0.027), and GRFS (HR = 0.51, p=4 x 10(-5)). Recipient age above 50 years was the only other factor associated with worse survivals. Conclusions: These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1186/s13045-016-0389-4en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAllogeneic stem cell transplantationen_US
dc.subjectHLA-matched related donoren_US
dc.subjectAcute myeloid leukemiaen_US
dc.subjectIn vivo T cell depletionen_US
dc.subjectGraft-versus-host diseaseen_US
dc.subjectRelapse incidenceen_US
dc.subjectGRFSen_US
dc.titleImpact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Partyen_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF HEMATOLOGY & ONCOLOGYen_US
dc.identifier.volume10en_US
dc.identifier.wos000396551100001en_US
dc.identifier.scopus2-s2.0-85009957310en_US
dc.contributor.pubmedID28118857en_US
dc.contributor.orcID0000-0002-8902-1283en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAD-5542-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster